Ottobock stock: At EUR 50.03, Ottobock stock falls 3.23 percent versus the Xetra close

Published on 10/21/2026 at 15:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Goldman cuts target from EUR 88.00 to EUR 75.00. Ottobock stock costs EUR 50.03 on October 21, 2026, down 3.23 percent versus the Xetra close.

Goldman target and earnings date

Goldman Sachs cut its Ottobock target from EUR 88.00 to EUR 75.00 on October 21, 2026.
Core revenue rose 11.70 percent to EUR 250.00 million in fiscal year 2025.
Ottobock stock costs EUR 50.03 at Lang & Schwarz on October 21, 2026 at 3:21 p.m. CEST, down 3.23 percent versus the Xetra close of October 20, 2026.
Ottobock is scheduled to publish its third-quarter 2026 report on November 12, 2026.

Ottobock, DE000BCK2223, Illustration mit AI erstellt.

Goldman Sachs cut its price target for Ottobock from EUR 88.00 to EUR 75.00 on October 21, 2026, while keeping its Buy rating, according to BÖRSE ONLINE. Ottobock stock was trading at EUR 50.03 at Lang & Schwarz on October 21, 2026 at 3:21 p.m. CEST, down 3.23 percent versus the Xetra close of October 20, 2026 at EUR 51.70.

Goldman trims target but keeps Buy

The reduction cuts the target by EUR 13.00, or 14.77 percent, from the previous EUR 88.00 level. The new EUR 75.00 target stands 49.91 percent above the Lang & Schwarz price, calculated from the same euro quotation. Goldman analyst Richard Felton linked the cautious near-term view to third-quarter revenue development and continued weakness in North America, while retaining a positive medium-term stance, finanzen.ch reported on October 21, 2026.

Revenue growth remains a key measure

Ottobock's core revenue rose 11.70 percent to EUR 250.00 million in fiscal year 2025. Adjusted EBITDA increased 29.50 percent to EUR 63.72 million, and the adjusted EBITDA margin reached 25.49 percent, up 3.60 percentage points, according to the company's investor-relations information dated October 21, 2026. Adjusted group profit rose 83.20 percent to EUR 27.20 million in the same fiscal year, Ottobock states.

What comes next for the stock?

The next scheduled corporate date is November 12, 2026, when Ottobock plans to publish its third-quarter 2026 report. The investor calendar also lists a BNP Paribas MidCap CEO Conference on November 16, 2026 and the Jefferies Global Healthcare Conference from November 18 to November 19, 2026.

Stock position after the decline

The current euro quotation places Ottobock EUR 1.67 below the October 20 Xetra close. The latest reported fiscal-year figures give investors two contrasting signals: core revenue rose 11.70 percent, while Goldman lowered its target by 14.77 percent. That combination makes the November reporting date the next concrete test for the revenue concerns cited in the analyst note.

Price and investor dates

Ottobock is a medical technology company focused on prosthetics, neuro-orthotics and exoskeletons. Its investor information describes operations in 45 countries, almost 9,300 full-time employees and more than 430 patient care centers worldwide. Those operating figures provide the business scale behind the listed company, while the latest target revision puts current valuation discussion in a more cautious frame.

Price after the Xetra close

Ottobock stock was trading at EUR 50.03 at Lang & Schwarz on October 21, 2026 at 3:21 p.m. CEST, down 3.23 percent versus the Xetra close of October 20, 2026 at EUR 51.70. The current price is 33.29 percent below the EUR 75.00 Goldman Sachs target.

The further course of trading is shown by the continuously updated real-time quote of Ottobock stock.